Research Projects

Dementia affects around 50 M people globally (mainly over 65 years old) and has high associated costs (~ $1 trillion per year). 60%-80% cases correspond to Alzheimer’s Disease (AD), which is expected to continue increasing exponentially in the next decades. At present, there are several disease-modifying treatments for AD in development, but once...

To the date there is no accurate scale to quantitatively measure motor dysfunction in neurological movement disorders. Doctors heavily relay on the information provided by the patients themselves. Objective data concerning the patient’s actual movements or seizures during their ordinary day would be very valuable for the doctors. The current common...

Brain plasticity and neuronal network oscillations are crucial brain processes that depend on the timing precision of neuronal activity. These processes change during healthy brain development and are disrupted early on Alzheimers disease (AD) with controversies on the onset of their impairment. Thus, comprehensive studies of plasticity considering...

Studies reported that bilingualism strengths executive functions in elderly and delays the Alzheimer’s disease (AD) onset for five years. These findings suggest that bilingualism enhances the cognitive reserve (CR). CR is a construct that includes a set of cognitively stimulating experiences (e.g. high education level, high occupational status)...

Cognitive deficits caused by ageing, neurodegenerative diseases or brain injury represent a major public health issue. They are associated with a disruption of neural oscillations in large-scale brain networks, which cannot be restored using current treatments. Here, I propose a new neuromodulation framework for manipulating neural oscillations...

Depressed mood, agitation, false beliefs, lack of motivation and other alterations in behaviour, usually named with the umbrella term of neuropsychiatric symptoms (NPS), are commonly observed in people with Alzheimers disease (AD). NPS are highly prevalent in people with AD (35-85%) and increase the risk of dementia by up to 10 times. The onset of...

Cerebral autoregulation and neurovascular coupling have a critical role in sustaining brain activity and preventing irreversible damage. Yet, despite revolutionary advances in neuroimaging methods questions remain on the relation and reciprocal interactions between cerebral hemodynamics (blood flow, oxygenation, vascular regulation) and neuronal...

Tauopathies, including Alzheimer’s Disease (AD), characterized by the brain accumulation of abnormal Tau proteins, represent a significant unmet medical need. Neuroinflammation is a hallmark of these diseases. Although several neuroimmune regulations, notably involving microglia, have been largely studied recently, the role of neutrophils and the...

Alzheimer’s disease (AD) and Parkinson’s disease (PD) are common in elderly and the prevalence of these is increasing. AD and PD have distinct pathogenesis, which precede the overt clinical symptoms by 10-15 years, opening a window for early diagnosis and treatment. New disease-modifying therapies are likely to be most efficient if initiated before...

NEKI is a technological company created by seasoned entrepreneurs from different fields like Programming, Marketing and Management. We brought our expertise to this company in order to implement advanced safety solutions for person location and real time communication to relatives or health professionals. Alzheimer and other cognitive impairments...

Alzheimer's disease (AD) is the most common form of dementia. Generally, it is diagnosed in people over 65 years of age, although the less prevalent early-onset Alzheimer's can occur much earlier. As of September 2010, this number is reported to be 35.6 million worldwide. AD develops for an indeterminate period of time before becoming fully...

The blood-brain barrier (BBB) is a major obstacle in treating diseases of the central nervous system (CNS) such as Parkinson's, Alzheimer's, Schizophrenia and brain cancer, affecting 180 million Europeans with less than 5% of current candidate drugs effectively reaching the brain. NAP4DIVE strives to revolutionize the traditionally expensive and...